Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study
Autore:
Paulussen, M; Ahrens, S; Lehnert, M; Taeger, D; Hense, HW; Wagner, A; Dunst, J; Harms, D; Reiter, A; Henze, G; Niemeyer, C; Gobel, U; Kremens, B; Folsch, UR; Aulitzky, WE; Voute, PA; Zoubek, A; Jurgens, H;
Indirizzi:
Univ Munster, Dept Pediat Hematol Oncol, D-48129 Munster, Germany Univ Munster Munster Germany D-48129 tol Oncol, D-48129 Munster, Germany Epidemiol Canc Registry Munster, Munster, Germany Epidemiol Canc Registry Munster Munster Germany nster, Munster, Germany Univ Munster, Dept Epidemiol & Social Med, D-4400 Munster, Germany Univ Munster Munster Germany D-4400 Social Med, D-4400 Munster, Germany Univ Halle, Dept Radiotherapy, Halle Saale, Germany Univ Halle Halle Saale Germany Dept Radiotherapy, Halle Saale, Germany Univ Kiel, Inst Paidopathol, D-24098 Kiel, Germany Univ Kiel Kiel Germany D-24098 , Inst Paidopathol, D-24098 Kiel, Germany Univ Giessen, Dept Pediat Hematol Oncol, D-35390 Giessen, Germany Univ Giessen Giessen Germany D-35390 tol Oncol, D-35390 Giessen, Germany Humboldt Univ, Dept Pediat Hematol Oncol, Berlin, Germany Humboldt Univ Berlin Germany Dept Pediat Hematol Oncol, Berlin, Germany Univ Freiburg, Dept Pediat Hematol Oncol, D-7800 Freiburg, Germany Univ Freiburg Freiburg Germany D-7800 ol Oncol, D-7800 Freiburg, Germany Univ Dusseldorf, Dept Pediat Hematol Oncol, D-4000 Dusseldorf, Germany Univ Dusseldorf Dusseldorf Germany D-4000 ol, D-4000 Dusseldorf, Germany Univ Essen Gesamthsch, Dept Pediat Hematol Oncol, D-4300 Essen 1, Germany Univ Essen Gesamthsch Essen Germany 1 tol Oncol, D-4300 Essen 1, Germany Univ Kiel, Dept Med Hematol Oncol, D-24098 Kiel, Germany Univ Kiel Kiel Germany D-24098 Med Hematol Oncol, D-24098 Kiel, Germany Robert Bosch Krankenhaus, Dept Med Hematol Oncol, Stuttgart, Germany Robert Bosch Krankenhaus Stuttgart Germany ol Oncol, Stuttgart, Germany Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol, NL-1012 WX Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1012 WX X Amsterdam, Netherlands St Anna Childrens Hosp, A-1090 Vienna, Austria St Anna Childrens Hosp Vienna Austria A-1090 osp, A-1090 Vienna, Austria
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 11, volume: 12, anno: 2001,
pagine: 1619 - 1630
SICI:
0923-7534(2001)12:11<1619:SMAETT>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; SHORT-TERM CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; PEDIATRIC-PATIENTS; SURVIVAL ANALYSIS; 2ND MALIGNANCIES; DOSE INTENSITY; BONE SARCOMAS; CHILDREN; INTERGROUP;
Keywords:
cytostatic drug therapy; Ewing tumors; second malignancies;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Paulussen, M Univ Munster, Dept Pediat Hematol Oncol, Albert Schweitzer Str 33, D-48129Munster, Germany Univ Munster Albert Schweitzer Str 33 Munster Germany D-48129
Citazione:
M. Paulussen et al., "Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study", ANN ONCOL, 12(11), 2001, pp. 1619-1630

Abstract

Background: Ewing tumor treatment involves high cumulative doses of alkylating agents and topoisomerase inhibitors, drugs capable of inducing second cancers. We analyzed the second cancer risk in a large cohort of consistently treated patients. Patients and methods: Six hundred ninety Ewing tumor patients were treatedbetween 1992 and 1999 with local therapy and vincristine, doxorubicin, ifosfamide and/or cyclophosphamide, and antinomycin D, with or without etoposide as a randomized question. Second cancer incidences were estimated by competing risk analyses; standardized incidence ratios (SIR) in comparison to registry data were compiled. Results:After a median observation time of 56 months (32 months for survivors), 6 of 690 patients had developed second cancers: MDS/AML, two, ALL/NHL, two, squamous cell carcinoma, one, liposarcoma, one. SIR were increased 20-30 fold in comparison to the general population. The cumulative second cancer risk five years after diagnosis of the Ewing tumor was 0.0093 for the total group, zero for patients without etoposide, and 0.0118 with etoposide. Additional phase II high-dose therapy increased the risk to 0.0398 after five years. Conclusions: The second cancder risk observed was in the range to be expected in cancer survivors. High-dose therapy, and less markedly, etoposide, may contribute to the overall second cancer risk.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 02:53:25